<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="164853">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01905397</url>
  </required_header>
  <id_info>
    <org_study_id>Pro00045975</org_study_id>
    <nct_id>NCT01905397</nct_id>
  </id_info>
  <brief_title>Negative Pressure Wound Therapy to Reduce Surgical Site Infection</brief_title>
  <official_title>Evaluation of Negative Pressure Wound Therapy for Reduction of Postoperative Surgical Site Infection in Patients Undergoing Colorectal and Hepatopancreatobiliary Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Duke University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Kinetic Concepts, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Duke University</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the rate of surgical site infection between
      traditional wound care and negative pressure wound therapy.  Wounds will be assessed 4-5
      days after surgery and at the first clinic visit after surgery.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2013</start_date>
  <completion_date type="Anticipated">September 2015</completion_date>
  <primary_completion_date type="Anticipated">September 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention</study_design>
  <primary_outcome>
    <measure>Incidence of Surgical Site Infection</measure>
    <time_frame>30 days post-surgery</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Characterization of surgical site infection</measure>
    <time_frame>30 days post-surgery</time_frame>
    <safety_issue>No</safety_issue>
    <description>Characterize the incidence of SSI as superficial incisional, deep incisional, and organ/space as defined by The American College of Surgeons NSQIP (National Surgical Quality Improvement Program) guidelines.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of hospital stay</measure>
    <time_frame>30 days post-surgery</time_frame>
    <safety_issue>No</safety_issue>
    <description>Assess (or compare) the length of hospital stay between subjects who receive standard of care and incisional V.A.C. via PIMS.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">126</enrollment>
  <condition>Patients Undergoing Hepatopancreatobiliary Surgery</condition>
  <arm_group>
    <arm_group_label>Negative Pressure Wound Therapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The Prevena Incision Management System is a 510K cleared device that covers and protects the incision from external infectious sources, while negative pressure removes fluid and infectious material from the surgical incision.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Conventional wound therapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Traditional wound therapy (sterile bandages and dressing)</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Conventional wound therapy</intervention_name>
    <description>Sterile bandages and wound coverings</description>
    <arm_group_label>Conventional wound therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Negative pressure wound therapy</intervention_name>
    <description>The Prevena Incision Management System covers and protects the incision from external infectious sources, while negative pressure removes fluid and infectious material from the surgical incision.</description>
    <arm_group_label>Negative Pressure Wound Therapy</arm_group_label>
    <other_name>Prevena Incision Management System</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Female and male patients 18 years of age or older

          -  Scheduled for an elective surgery in either open CRS or open HPBS. This includes:
             ileocecectomy, right hemicolectomy, extended right hemicolectomy, transverse
             colectomy, left hemicolectomy, sigmoidectomy, proctectomy, low anterior resection, or
             abdominoperineal resection gastrectomy, hepatectomy, bile duct reconstruction,
             duodenectomy, pancreatectomy, pancreaticoduodenectomy, or pancreatic duct
             reconstruction

        Exclusion Criteria:

          -  The need for emergency surgery.

          -  The need for use of only laparoscopic surgery.

          -  Presence of bowel obstruction, strangulation, peritonitis or perforation.

          -  The presence of local or systemic infection preoperatively.

          -  ASA class â‰¥4.

          -  Abdominal surgical incision &lt; 7 cm.

          -  Inability to provide informed consent and authorization.

          -  Known allergy or hypersensitivity to silver.

          -  Any clinically significant condition that, in the investigator's opinion, would
             significantly                     impair the subject's ability to comply with the
             study.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Trey Blazer, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Duke University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Brant Hamel, PhD</last_name>
    <phone>919-668-1861</phone>
    <email>Brant.Hamel@duke.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anthony Amara, MSW</last_name>
      <phone>919-668-1861</phone>
      <email>Anthony.Amara@duke.edu</email>
    </contact>
    <contact_backup>
      <last_name>Wanda Honeycutt, RN</last_name>
      <phone>919-668-1861</phone>
      <email>Wanda.Honeycutt@duke.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Dan Blazer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <lastchanged_date>April 9, 2014</lastchanged_date>
  <firstreceived_date>July 18, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
